Navigation Links
Phase 3 Results for Alogliptin Demonstrated Significant Blood Sugar Reductions in Monotherapy and Four Add-on Therapy Studies
Date:6/7/2008

Data from five pivotal phase 3 studies presented at the American Diabetes

Association 68th Scientific Sessions

SAN FRANCISCO, June 7 /PRNewswire/ -- Results from five pivotal phase 3 studies of alogliptin were announced today at the American Diabetes Association (ADA) 68th Scientific Sessions by Takeda Global Research & Development Center, Inc. Alogliptin, which has been shown to be a highly selective inhibitor of dipeptidyl peptidase-4 (DPP-4), is currently under investigation as an oral treatment for type 2 diabetes. Alogliptin administered once daily demonstrated statistically significant reductions in hemoglobin A1c (HbA1c) versus placebo as a monotherapy and as an add-on therapy with the major classes of type 2 diabetes medications: metformin, thiazolidinediones, insulin and sulfonylureas.

"Almost half the patients with type 2 diabetes are not at the American Diabetes Association recommended HbA1c goal of less than 7 percent, so it's important to have new treatment options that are both effective and well tolerated to potentially address the large number of patients who aren't adequately controlled," said Richard Pratley, MD, director of the Diabetes & Metabolism Translational Medicine Unit at the University of Vermont College of Medicine. "These clinical data show that alogliptin effectively reduces blood sugar in patients, alone or when used in combination with existing oral anti-diabetic treatments as well as insulin, increasing the range of treatment options for patients."

In the alogliptin monotherapy study, a significantly greater percentage of patients achieved HbA1c levels of less than or equal to 7 percent. Similar results were seen in the add-on to metformin, thiazolidinedione and sulfonylurea studies. Across all studies, patients achieved significant reductions in HbA1c, up to 0.80 percent, depending on the alogliptin dose and their treatment regimen. Greater HbA1c reductions were seen in patients with h
'/>"/>

SOURCE Takeda Global Research & Development
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. New Diabetes Compound AVE0010 Showed Clear Dose Response Results With Once-A-Day Injection in Phase IIb Study
2. Synvista Therapeutics Reports Results of Three Phase 2 Clinical Trials of SYI-2074 in Diabetic Patients with Cardiovascular Disease
3. Phase 1/2 Trial of Motexafin Gadolinium Plus Antibody Targeted Radiation Therapy Demonstrates High Complete Response Rate in Patients With Non-Hodgkins Lymphoma
4. Nuvelo Initiates Phase 1B Clinical Trial of Anticoagulant NU172
5. Semafore Pharmaceuticals Reports Positive Interim Results from a Phase I Study of SF1126, a Targeted Pan-PI3K Inhibitor, in Patients with Advanced Solid Tumors
6. Celator(R) Pharmaceuticals Announces Positive Phase 2 Results for CPX-1 in Treatment of Colorectal Cancer
7. Keryx Biopharmaceuticals, Inc. Announces Phase 2 Results on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Waldenstroms Macroglobulinemia at the 44th Annual Meeting of the American Society of Clinical Oncology
8. Delcath Expands Phase III Trial for Metastatic Melanoma to Include St. Lukes Cancer Center
9. Kosans Lead Hsp90 Inhibitor, Tanespimycin, Shows High Level of Activity in Trastuzumab Resistant/Refractory HER2-Positive Breast Cancer in a Phase 2 Trial
10. Amicus Therapeutics Begins Phase 2 Clinical Trial of AT2220 in Pompe Disease
11. EntreMed Presents MKC-1 Phase 2 Data at American Society of Clinical Oncology Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... 11. Juli 2014  Dilon Technologies, ... die molekulare Bildgebung, einschließlich molekularer Bildgebung ... CE-Zulassung für sein Navigator ® -Gamma-Sondensystem ... das Produkt jetzt europaweit vertreiben. Dilon ... der europäischen Länder ausgedehnt und bereits ...
(Date:7/10/2014)... SAN DIEGO , July 10, 2014  RESMED INC. ... report its fourth quarter and fiscal year ended June 30, ... York Stock Exchange market close. A press release with ResMed,s ... and the company will host a webcast to discuss operating ... scheduled to begin at 1:30 p.m. US Pacific Time and ...
(Date:7/10/2014)... , July 10, 2014   Ventana Medical Systems, ... announced it has entered into an agreement with Merck ... as EMD Serono in the United States ... collaborate with Merck KGaA,s biopharmaceutical division on the development ... undisclosed target using Ventana,s proprietary diagnostic assays. In alignment ...
Breaking Medicine Technology:Dilon erhält CE-Zulassung für sein Navigator-Gamma-Sondensystem 2ResMed To Announce Fourth Quarter And Fiscal Year-End 2014 Results 2Ventana Medical Systems, Inc. and Merck KGaA, Darmstadt, Germany to develop companion diagnostic test for cancer treatment 2Ventana Medical Systems, Inc. and Merck KGaA, Darmstadt, Germany to develop companion diagnostic test for cancer treatment 3
(Date:7/12/2014)... July 12, 2014 Demand Response Management ... considerable benefits in reducing the imbalance between energy supply ... appliances have been rolled out (due to increasing pressure ... (AMI). This helps in controlling residential appliances and thermostats ... in the North American region, and with government mandates ...
(Date:7/12/2014)... make exercise fun, you,ll eat less after your workout, new ... on a 1.4-mile walk and were either told it would ... were given lunch after the walk, and those who were ... chocolate pudding for dessert than those who were told it ... were given mid-afternoon snacks after their walk. Those who were ...
(Date:7/12/2014)... Using and carrying around a catheter ... from Ashland, Va., decided that there needed to be ... to conceive of our design," he said. , They ... which provides an inconspicuous way to use and carry ... as promotes comfort and peace of mind. Producible in ...
(Date:7/12/2014)... 12, 2014 “Critical Care Therapeutics ... and Late-Stage Four-Factor PCCs and Recombinant Products to ... critical care market in the US, UK, France, ... provides an estimation of market size for 2013, ... critical care indications that are being treated using ...
(Date:7/12/2014)... A recent article released by Seattle's well ... suggestions for those seeking cosmetic surgical procedures in summer ... and the heat begins to enliven the rainy Pacific Northwest, ... realizing that they didn’t work out as much during the ... a sudden surge of people eager to look their best ...
Breaking Medicine News(10 mins):Health News:North America Demand Response Management System Worth $12,522.4 Million by 2019 - New Report by MicroMarket Monitor 2Health News:North America Demand Response Management System Worth $12,522.4 Million by 2019 - New Report by MicroMarket Monitor 3Health News:North America Demand Response Management System Worth $12,522.4 Million by 2019 - New Report by MicroMarket Monitor 4Health News:Make Exercise Fun, Eat Less Afterwards 2Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 2Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 3Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 4Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 5Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 6Health News:Best Summer Cosmetic Surgeries Revealed in Article By Seattle Plastic Surgeon 2
... as 10-fold, researchers find, , MONDAY, Sept. 7 (HealthDay ... minor infection can double the rate of memory loss, ... found that Alzheimer,s patients who had respiratory, gastrointestinal or ... can have high levels of tumor necrosis factor-alpha (TNF-a), ...
... minor complications seen with ,after-hours, procedures, study finds , ... daytime slot to undergo an orthopedic procedure may lower ... a new study has found. , The study, ... of Bone and Joint Surgery , found little difference ...
... 7 Bounty, the UK,s favourite parenting,club, today launches a 4 ... mums take a real life, close up peek at how a ... To view the Multimedia News Release, please click: , ... Breastfeeding is the healthiest and most natural way to feed a ...
... , , , ... Stemedica Cell Technologies, Inc., ("Stemedica"), a world leader in stem cell ... its breakthrough stem cell and related technology. The Jordanian Stem ... purchase the technology from Stemedica,s wholly-owned subsidiary, Stemedica International, S.A. ...
... in clearance of amyloid plaque from brain , SUNDAY, ... scientists have uncovered three gene variants that up the ... dementia among the elderly and the seventh-leading cause of ... Dr. Philippe Amouyel of the Institut Pasteur de Lille ...
... ... the grand opening of the new rehabilitation hospital with partner HealthSouth. , ... Mesa, Ariz. (PRWEB) September 6, ... on August 18 to welcome the rehabilitation hospital to the East Valley and ...
Cached Medicine News:Health News:Even Mild Infections Hasten Decline With Alzheimer's 2Health News:Even Mild Infections Hasten Decline With Alzheimer's 3Health News:Let Orthopedic Surgery Wait Until Morning When Possible 2Health News:Bounty Parenting Club Launches View on Demand 'How to Breastfeed' Video 2Health News:The Jordanian Stem Cell Company Acquires Stem Cell Technology From Stemedica International S.A. 2Health News:The Jordanian Stem Cell Company Acquires Stem Cell Technology From Stemedica International S.A. 3Health News:Trio of Gene Variants Discovered That May Raise Alzheimer's Risk 2Health News:Trio of Gene Variants Discovered That May Raise Alzheimer's Risk 3Health News:ATSU Arizona Health & Technology Park Partner HealthSouth Holds Grand Opening 2
... Pro Osteon Bone Graft Substitutes a natural ... from cadaver bone, but such grafts may ... disease transmission. Interpore Cross has developed the ... to address these needs, offering surgeons a ...
... Healos is an osteoconductive matrix constructed ... fully coated with hydroxyapatite through a ... with autogenous bone marrow aspirate, Healos ... cell attachment, proliferation and differentiation. The ...
Weitlaner-Locktite retractors, blunt, 11 cm total length....
Sharp Weitlaner Retractor....
Medicine Products: